GlobeNewswire by notified

Sampo returns excess capital following Nordea exit

Share

SAMPO PLC         STOCK EXCHANGE RELEASE           9 June 2022 at 5:05 pm

Sampo returns excess capital following Nordea exit

On 29 April 2022, Sampo plc completed the exit from Nordea through a disposal of EUR 1.8 billion worth of shares, leaving the group with substantial excess capital relative to its targets on solvency (170–190 per cent) and financial leverage (below 30 per cent).

In line with the Group’s commitment to capital efficiency, the Board of Directors has today resolved to launch a EUR 1 billion share buyback programme. In addition, management intends to propose to the Board of Directors a second distribution of capital in the form of a share buyback programme or extra dividend, or a combination thereof, in connection with the publication of the 2022 financial result on 9 February 2023. As in previous years, the Board of Directors will also publish its proposal for the distribution of dividend on this date.

Launch of new share buyback programme

The buyback programme announced today is based on the authorisation granted by the Annual General Meeting held on 18 May 2022. The aggregate purchase price of the Sampo A shares acquired under the programme shall not exceed EUR 1 billion and the maximum number of shares that can be repurchased is 30 million, corresponding to 5.6 per cent of the total number of shares in Sampo. The programme will start at the earliest on 10 June 2022 and end no later than 8 February 2023. The buyback programme will reduce Sampo plc’s funds available for distribution of profit. The repurchased shares will be cancelled.

The purchase price per share shall be no more than the highest price paid for the company’s shares in public trading on the day of the repurchase or the offer to repurchase the company’s own shares, or alternatively, the average of the share prices (volume weighted average price on the regulated markets where the company’s share is admitted to trading) during the five trading days preceding the repurchase or the offer to repurchase the company’s own shares. The lowest purchase price per share shall be the price that is 20 per cent lower than the lowest price paid for the company’s shares in public trading during the validity of this authorisation until the repurchase or the offer to repurchase the company’s own shares. The shares will be acquired through public trading on Nasdaq Helsinki, CBOE, Turquoise and Aquis.

The repurchases will be made in accordance with the safe harbour arrangement of Article 5 of the EU Market Abuse Regulation. Sampo has appointed BNP Paribas Exane as the lead manager for the share buyback programme. The lead manager will make trading decisions independently of and without influence from Sampo, within the announced limits.

SAMPO PLC
Board of Directors

For further information, please contact:

Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030

Maria Silander
Communications Manager, Media Relations
tel. +358 10 516 0031

Distribution:
Nasdaq Helsinki
London Stock Exchange
The principal media
Financial Supervisory Authority
www.sampo.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo

Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form